FUJIFILM Corporation has invested $200 million in two subsidiaries to expand global cell therapy contract development and manufacturing (CDMO) capabilities. 

The investment is earmarked for both the new headquarters of FUJIFILM Cellular Dynamics, Inc., a global developer, and manufacturer of human induced pluripotent stem cells (iPSC) and iPSC-derived cells, and the California site of FUJIFILM Diosynth Biotechnologies, a biologics and advanced therapies CDMO.

The investment will strengthen Fujifilm’s manufacturing capacity to support iPSC-derived cell therapies, as well as Cytoxic T lymphocyte (CTL), Chimeric antigen receptor (CAR), T-cell receptor (TCR), Natural killer (NK) and tissue-derived therapies.

The investment will also fund FUJIFILM Cellular Dynamics’ new 175,000 sq.-ft headquarters in Madison, WI. The new campus will house iPSC cGMP manufacturing with three clean room suites, process development laboratories, warehouse operations and administrative space.

In addition, the investment will double the company’s existing manufacturing capacity for the development and commercialization of iPSC-derived cell therapies for its partners. The new site will also include iPSC manufacturing for research and development applications for drug discovery, drug efficacy, and pharmacology. The site, including cell therapy manufacturing, will be operational in spring 2026.

The investment in FUJIFILM Diosynth Biotechnologies’ site in Thousand Oaks, CA, will fund the site expansion with a new development lab and two new independent manufacturing clean rooms, significantly increasing production capacity for new client programs. The California site provides clinical and commercial manufacturing of in vitro cell lines, targeting a wide variety of cell therapies. The added capacity will be operational in early 2025.

“This investment is an important step for Fujifilm to lead as an innovative global manufacturing partner for the growing cell therapy market,” said Teiichi Goto, President and CEO, representative director, FUJIFILM Corporation. “The combined resources of the Fujifilm Group will enable us to meet the diverse and expanding manufacturing needs of our customers. We look forward to supporting our customers in manufacturing cell therapies that address unmet medical needs and contribute to the advancement of human health worldwide.”